ROC
Alternative Name: Ulipristal acetate (UPA) Oral
Description: An estrogen-free, daily low dose oral of a selective progesterone receptor modulator, ulipristal acetate (UPA).
Product Details
User: Female
Hormonal: Yes
Delivery Method: Oral
Duration Type: Short-acting
Duration: One day
Regimen: - daily
- daily
Dose: 10 mg
Active Pharmaceutical Ingredient (API): - ulipristal acetate
- ulipristal acetate
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: HRA Pharma, NICHD
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase II
Active Development: Yes
Status Details: - A phase II clinical trial to assess efficacy, safety, and acceptability is ongoing under the auspices of the NICHD Contraceptive Clinical Trials Network.
- A phase II clinical trial to assess efficacy, safety, and acceptability is ongoing under the auspices of the NICHD Contraceptive Clinical Trials Network.
Additional Information
References: HRA Pharma website: www.hra-pharma.com/
ClinicalTrials.gov Identified NCT03296098
HRA Pharma website: www.hra-pharma.com/
ClinicalTrials.gov Identified NCT03296098